TITLE:
Leucocytosis Predicts Survival in Metastatic Non Small Cell Lung Carcinoma Patients—A Retrospective Review of a Single Institution Data
AUTHORS:
Lamiae Amaadour, Zineb Benbrahim, Nadia Benaicha, Fatima Zahra Elmrabet, Samia Arifi, Chakib Nejjari, Nawfel Mellas
KEYWORDS:
Paraneoplastic Leucocytosis, NSCLC, Metastatic Stage, Survival
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.8 No.11,
November
21,
2017
ABSTRACT: Background: Tumor-related leukocytosis
is a paraneoplastic syndrome that is encountered occasionally in the clinical
course of patients with lung carcinoma. The aim of this study is to evaluate the
prognostic significance of leucocytosis in patients with metastatic non small
cell lung carcinoma. Methods: We retrospectively reviewed 205 cases of
metastatic non small cell lung carcinoma diagnosed between January 2007 and
December 2012 at the department of medical oncology, Hassan II University
Hospital of Fez, Morocco. Clinical and laboratory data were collected including
white blood cells at baseline. Leucocytosis was studied in relation to overall
survival and progression free survival. Results: The frequency of
leucocytosis was of 57.5%. Patients with leucocytosis had shorter overall
survival (OS, p = 0.015) and disease-free survival (DFS, p 0.0001) than
those without leucocytosis. In multivariable analysis, patients with
leucocytosis had a significantly greater risk of death and recurrence than
those without leucocytosis. Conclusion: Leucocytosis was valuable for
predicting the prognosis of patients with metastatic non small cell lung
carcinoma.